Tags : Evaluation


GSK Signs a Research Collaboration with Clover for the Evaluation

Shots: GSK to provide pandemic adjuvant system to Clover to evaluate S-Trimer in preclinical studies while Clover has largest commercial-scale cGMP biomanufacturing capabilities in China involved in rapid scale-up and produce new coronavirus vaccine The focus of the collaboration is to evaluate the combination of GSK’s pandemic adjuvant system with Clover’s S-Trimer as a vaccine […]Read More


Arcellx Signs a Development Evaluation and License Agreement with Pfenex

Shots: Pfenex to receive R&D funding along with $2.6M up to $18M as development, regulatory & commercial milestones and royalties on WW sales of products. Arcellx to get access to Pfenex expression technology platform to advance sparX proteins, activating, silencing & reprograming antigen- receptor complex T-cell based therapies Arcellx’s first sparX protein has completed its […]Read More


Boehringer Ingelheim Signs a Clinical Research Agreement with Amal for

Shots: Boehringer Ingelheim (BI) and Amal Therapeutics enter into a clinical research agreement to conduct P-Ib KISIMA-01 study assessing Amal’s ATP128 and BI’s BI754091 with microsatellite stable (MSS) patients with stage IV colorectal cancer Amal to sponsor the P-Ib KISIMA-01 and will retain development & commercialization rights for ATP128 and the KISIMA technology. BI to […]Read More


Pfizer and Atomwise Signs an Evaluation Agreement to Identify Potential

Shots: Pfizer will pay access fee for using Atomwise’s AI technology with success-based payments for each target protein selected, while Atomwise will computationally analyse various small molecules for each of Pfizer’s identified target proteins Additionally, Atomwise medicinal and computational chemistry team will work collaboratively with Pfizer scientists to identify potency and chemical properties of the […]Read More